Clinical Trial Update: Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports ongoing Phase 1/2 testing of the combination epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell non-Hodg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Diffuse Large B-cell Lymphoma Transformed
• Follicular Lymphoma Grade 3b
• High-grade B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma with Myc Bcl2 and Bcl6 Rearrangements
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements
• Mediastinal Large B-cell Lymphoma
• Transformed Non-hodgkin Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)
• Ibrutinib (ibrutinib)

Snippet

Sponsor: Yazeed Sawalha | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 1, Phase 2 | Status: RECRUITING